Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  inflammatory breast cancer
Trial Type:  Treatment
Results 1-12 of 12 for your search:
Start Over
Romidepsin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Inflammatory Breast Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 13C.387, NCI-2013-01695, 080-38270-J94401, 2013-35, NCT01938833
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 097517, NCI-2015-00014, NCT01042379
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation before Surgery in Treating Patients with Locally Advanced or Inflammatory Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 11174, NCI-2012-00025, 103352, 109696, 110312, 118191, NCT01525966
Ruxolitinib Phosphate in Treating Patients with Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-024, NCI-2012-00992, NCT01562873
Paclitaxel, Trastuzumab, and Pertuzumab before Surgery in Treating Patients with Inflammatory Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-497, NCI-2013-01110, ML28193, NCT01796197
Nintedanib in Treating Patients with Metastatic HER2-Negative Inflammatory Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0464, NCI-2015-00506, NCT02389764
Pembrolizumab in Treating Patients with Stage IV Metastatic or Recurrent Inflammatory Breast Cancer Who Have Received Prior Chemotherapy with Clinical Response
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0533, NCI-2015-00671, NCT02411656
Carboplatin and Paclitaxel with Pertuzumab and Trastuzumab or Bevacizumab in Treating Patients with Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UCI 14-67, NCI-2015-02066, NCT02436993
Talimogene Laherparepvec in Treating Patients with Recurrent Breast Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0034, NCI-2016-00199, NCT02658812
Eribulin Mesylate Followed by Doxorubicin Hydrochloride and Cyclophosphamide in Treating Patients with HER2-negative Inflammatory Breast Cancer before Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-292, NCI-2016-00329, NCT02623972
Ipilimumab and Nivolumab in Treating Patients with Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 16B07, NCI-2016-01038, STU00203191, NCT02892734
Dose-escalation Study of Oral CX-4945
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C4-08-001, NCI-2009-01571, NCT00891280
Start Over